Using analytics and bioassays to de-risk your mRNA LNP drug development programme
Pharmaceutical Technology
FEBRUARY 15, 2023
The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. More challenges arise with the formulation of the mRNA delivery agent, like lipid nanoparticles (LNPs). Where is your payload?
130 
Let's personalize your content